EGFR exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib

Documenti analoghi

• EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
  di: Arcila, Maria E, et al.
  Pubblicazione: (2013)
• EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
  di: He, Mai, et al.
  Pubblicazione: (2011)
• Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions
  di: Choudhury, Noura J., et al.
  Pubblicazione: (2021)
• Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
  di: Murano, Chihiro, et al.
  Pubblicazione: (2019)
• Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
  di: Oxnard, Geoffrey R., et al.
  Pubblicazione: (2011)